Compare Opendoor Technologies Inc (OPEN) vs TG Therapeutics Inc (TGTX) Price & Performance

Opendoor Technologies (OPEN) trades at $4.48, down 0.44% on the day, with a bearish technical outlook and mixed fundamental signals. The stock shows a low price-to-sales ratio of 0.93 but suffers from significant losses, with a net income margin of -35.25% and negative ROE of -173.61%. Recent earnings have been volatile, missing estimates in Q1 2026. Cash flow improved in 2025 with net cash flow of $538 million, though revenue declined to $4.37 billion. News highlights include the upcoming Q2 2026 earnings report and strategic shifts like closing India operations to focus on AI.

The outlook remains challenging due to persistent losses and a tough housing market, but cost-cutting and operational adjustments under new CEO Kaz Nejatian offer potential for margin improvement. Risks include high debt, competitive pressure from Zillow, and interest rate sensitivity. Analyst sentiment is cautious with 65.39% hold ratings, reflecting uncertainty about sustainable profitability. Investors should weigh the low valuation against execution risks in a volatile sector.

TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.

The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.